Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Elez ME"'
Autor:
Fucà, Giovanni, Cohen, Romain, Lonardi, Sara, Shitara, Kohei, Elez, Elena, Fakih, Marwan, Chao, Joseph, Klempner, Samuel J., Emmett, Matthew, Jayachandran, Priya, Bergamo, Francesca, García, Marc Díez, Mazzoli, Giacomo, Provenzano, Leonardo, Colle, Raphael, Svrcek, Magali, Ambrosini, Margherita, Randon, Giovanni, Shah, Aakash Tushar, Salati, Massimiliano, Fenocchio, Elisabetta, Salvatore, Lisa, Chida, Keigo, Kawazoe, Akihito, Conca, Veronica, Curigliano, Giuseppe, Corti, Francesca, Cremolini, Chiara, Overman, Michael, Andre, Thierry, Pietrantonio, Filippo, Universitat Autònoma de Barcelona
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2022, 10 (2), pp.e004001. ⟨10.1136/jitc-2021-004001⟩
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Scientia
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Journal for Immunotherapy of Cancer, 2022, 10 (2), pp.e004001. ⟨10.1136/jitc-2021-004001⟩
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Scientia
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
BackgroundDespite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows prim
Autor:
Giuseppe Curigliano, Michael J. Overman, Massimiliano Salati, Chiara Cremolini, Aakash Tushar Shah, Gabriele Infante, Sara Lonardi, Rossana Intini, Priya Jayachandran, Giovanni Fucà, Floriana Nappo, Rosalba Miceli, Marwan Fakih, Francesca Corti, Lisa Salvatore, Federica Morano, Javier Ros, Filippo Pietrantonio, Margherita Ambrosini, Elisabetta Fenocchio, Silvia Damian, Maria Elena Elez
Publikováno v:
Scientia
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Neoplasias gastrointestinales; Inmunoterapia Neoplàsies gastrointestinals; Immunoteràpia Gastrointestinal neoplasms; Immunotherapy Background The efficacy of immune checkpoint inhibitors (ICIs) in patients with microsatellite instability (MSI)-high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b24c8cbd2319d4ea7771de79ebb64444
https://hdl.handle.net/11351/7373
https://hdl.handle.net/11351/7373
Autor:
Nasca V; Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy., Barretta F; Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy., Corti F; Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy., Lonardi S; Department of Medical Oncology, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy., Niger M; Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy., Elez ME; Medical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Fakih M; Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center Duarte, Duarte, California, USA., Jayachandran P; Oncology, University of Southern California, Los Angeles, California, USA., Shah AT; Baylor College of Medicine, Houston, Texas, USA., Salati M; Department of Medical Oncology, University Hospital Modena, Modena, Italy., Fenocchio E; Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, Candiolo, Italy., Salvatore L; Oncologia Medica, Università Cattolica del Sacro Cuore, Roma, Italy.; Cancer Comprehensive Center, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy., Cremolini C; Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., Ros J; Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Hospital Vall Hebron, Vall d'Hebron University Hospital, Barcelona, Spain., Ambrosini M; Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy., Mazzoli G; Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy., Intini R; Department of Oncology, IRCCS Istituto Oncologico Veneto, Padova, Italy., Overman MJ; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Miceli R; Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy., Pietrantonio F; Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy filippo.pietrantonio@istitutotumori.mi.it.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Jan; Vol. 11 (1).
Autor:
Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy filippo.pietrantonio@istitutotumori.mi.it., Lonardi S; Medical Oncology 3, Istituto Oncologico Veneto IOV-IRCSS, Padua, Italy., Corti F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Infante G; Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Elez ME; Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain., Fakih M; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California, USA., Jayachandran P; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA., Shah AT; Baylor College of Medicine, Houston, Texas, USA., Salati M; Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, PhD Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, Italy., Fenocchio E; Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy., Salvatore L; Department of Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Curigliano G; European Institute of Oncology (IEO), IRCCS, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy., Cremolini C; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Ambrosini M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ros J; Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain., Intini R; Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy., Nappo F; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy., Damian S; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Morano F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Fucà G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Overman M; Department of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Miceli R; Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Aug; Vol. 9 (8).
Autor:
Santos C; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Translational Research Laboratory, ICO-Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain., Azuara D; Traslational Research Laboratory, ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Garcia-Carbonero R; Department of Medical Oncology, Hospital Doce de Octubre, CIBERONC, Madrid, Spain., Alfonso PG; Department of Medical Oncology, Hospital Gregorio Marañón, Madrid, Spain., Carrato A; Department of Medical Oncology, Hospital Ramón y Cajal, IRYCIS, CIBERONC, Alcala University, Madrid, Spain., Elez ME; Department of Medical Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain., Gomez A; Department of Medical Oncology IMIBIC, Reina Sofía Hospital, University of Córdoba, Red Temática de Investigación Cooperativa en Cáncer (RTICC). Instituto de Salud Carlos III, Spain., Losa F; Department of Medical Oncology, Catalan Institute of Oncology, San Joan Despí, Barcelona, Spain., Montagut C; Department of Medical Oncology, Del Mar University Hospital, Barcelona, Spain., Massuti B; Department of Medical Oncology, Hospital General Universitario, Alicante, Spain., Navarro V; Clinical Research Unit, ICO, L'Hospitalet, Barcelona, Spain., Varela M; Department of Pathology, Bellvitge University Hospital, L'Hospitalet, Barcelona, Spain., Lopez-Doriga A; Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, ICO - IDIBELL and CIBERESP, L'Hospitalet, Barcelona, Spain., Moreno V; Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, ICO - IDIBELL and CIBERESP, L'Hospitalet, Barcelona, Spain.; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Spain., Valladares M; Department of Medical Oncology, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., Manzano JL; Department of Medical Oncology, ICO, Badalona, Barcelona, Spain., Vieitez JM; Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain., Aranda E; Department of Medical Oncology IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC Instituto de Salud Carlos III, Spain., Sanjuan X; Department of Pathology, Bellvitge University Hospital, L'Hospitalet, Barcelona, Spain., Tabernero J; Department of Medical Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.; CIBERONC Instituto de Salud Carlos III, Spain., Capella G; Traslational Research Laboratory, ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Spain.; CIBERONC Instituto de Salud Carlos III, Spain., Salazar R; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Translational Research Laboratory, ICO-Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain. ramonsalazar@iconcologia.net.; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Spain.; CIBERONC Instituto de Salud Carlos III, Spain.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2017 Sep; Vol. 16 (9), pp. 1999-2007. Date of Electronic Publication: 2017 Jun 16.
Autor:
Sanz-Garcia E; a Department of Medical Oncology , Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona , 08035 Barcelona , Spain., Grasselli J; b Department of Medical Oncology , Vall d'Hebron Institute of Oncology , 08035 Barcelona , Spain.; c Department of Medical Oncology , Instituto Català de Oncologia , 08907 Barcelona , Spain., Argiles G; a Department of Medical Oncology , Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona , 08035 Barcelona , Spain.; b Department of Medical Oncology , Vall d'Hebron Institute of Oncology , 08035 Barcelona , Spain., Elez ME; a Department of Medical Oncology , Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona , 08035 Barcelona , Spain.; b Department of Medical Oncology , Vall d'Hebron Institute of Oncology , 08035 Barcelona , Spain., Tabernero J; a Department of Medical Oncology , Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona , 08035 Barcelona , Spain.; b Department of Medical Oncology , Vall d'Hebron Institute of Oncology , 08035 Barcelona , Spain.
Publikováno v:
Expert opinion on biological therapy [Expert Opin Biol Ther] 2016; Vol. 16 (1), pp. 93-110. Date of Electronic Publication: 2015 Nov 07.
Autor:
Tabernero J; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York jtabernero@vhio.net., Elez ME; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Herranz M; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Rico I; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Prudkin L; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Andreu J; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Mateos J; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Carreras MJ; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Han M; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Gifford J; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Credi M; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Yin W; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Agarwal S; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Komarnitsky P; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York., Baselga J; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2014 May 15; Vol. 20 (10), pp. 2793-804. Date of Electronic Publication: 2014 Mar 14.
Autor:
Elez ME; Authors' Affiliations: Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona; PharmaMar, S.A., Colmenar Viejo, Madrid, Spain; and Department of Medicine, The University of Chicago, Chicago, Illinois., Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2014 Apr 15; Vol. 20 (8), pp. 2205-14. Date of Electronic Publication: 2014 Feb 21.
Autor:
Puig I; Authors' Affiliations: Translational Program, Stem Cells and Cancer Laboratory; Molecular Oncology Group; Genomics Cancer Group; and Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO); Parc de Recerca Biomèdica de Barcelona (PRBB), Centre d'Imatge Molecular (CRC) Corporació Sanitària; Departments of Pathology, Medical Oncology, and HBP Surgery and Transplantation, Vall d'Hebron University Hospital, Universidad Autónoma de Barcelona; and General Surgery Service, Vall d'Hebron University Hospital, Barcelona, Spain., Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argilés G, Vivancos A, Tabernero J, Rojas S, Palmer HG
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2013 Dec 15; Vol. 19 (24), pp. 6787-801. Date of Electronic Publication: 2013 Oct 29.
Autor:
Siena S; Ospedale Niguarda Ca' Granda, Milan, Italy., Van Cutsem E, Li M, Jungnelius U, Romano A, Beck R, Bencardino K, Elez ME, Prenen H, Sanchis M, Sartore-Bianchi A, Tejpar S, Gandhi A, Shi T, Tabernero J
Publikováno v:
PloS one [PLoS One] 2013 Nov 11; Vol. 8 (11), pp. e62264. Date of Electronic Publication: 2013 Nov 11 (Print Publication: 2013).